OPRX
NEUTRAL
$6.4
Live
OptimizeRx Corporation · NASDAQ
Target $14.5
(+126.6%)
$5.54
52W Range
$22.25
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Confidence
80%
OPRX presents a complex profile with a stable Piotroski F-Score of 4/9 and a current price ($6.40) aligned almost perfectly with its Graham Number ($6.45). While the balance sheet is exceptionally clean with low debt (0.20 D/E) and high liquidity (3.04 Current Ratio), the company suffers from stagnant revenue growth (-0.20% YoY) and a severe technical downtrend. The massive discrepancy between the growth-based intrinsic value ($1.89) and the analyst target ($14.50) suggests a high-risk turnaround play rather than a stable value investment.
Key Strengths
Strong liquidity position with a Current Ratio of 3.04
Very low leverage with Debt/Equity at 0.20
Impressive earnings surprise track record (Avg 622% over last 4 quarters)
Attractive Forward P/E of 5.75 suggesting significant earnings expansion
Trading slightly below book value (P/B 0.94)
Key Risks
Stagnant top-line growth with YoY revenue growth at -0.20%
Severe negative price momentum (68.6% decline in last 6 months)
Bearish insider sentiment with CFO selling shares
Significant gap between growth-based intrinsic value ($1.89) and market price
Lack of dividend support or shareholder yield
AI Fair Value Estimate
Based on comprehensive analysis
$6.45
+0.8% above current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare OPRX against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning OPRX from our newsroom.
Newest → oldest
No matching news yet.